Equities research analysts at Royal Bank Of Canada started coverage on shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) in a note issued to investors on Wednesday. The brokerage set an “outperform” rating and a $11.00 price target on the biopharmaceutical company’s stock. Royal Bank Of Canada’s price target points to a potential upside of 76.28% from the company’s current price.

A number of other research analysts have also weighed in on INO. HC Wainwright set a $13.00 target price on Inovio Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, July 7th. Zacks Investment Research raised Inovio Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.75 target price on the stock in a report on Tuesday, July 11th. Aegis reissued a “buy” rating and set a $14.00 target price on shares of Inovio Pharmaceuticals in a report on Tuesday, July 18th. BidaskClub lowered Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, July 28th. Finally, Maxim Group set a $12.00 target price on Inovio Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, August 9th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and eight have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $19.16.

Inovio Pharmaceuticals (NASDAQ INO) opened at 6.24 on Wednesday. Inovio Pharmaceuticals has a one year low of $5.28 and a one year high of $9.86. The firm’s market cap is $563.02 million. The firm’s 50-day moving average price is $6.18 and its 200 day moving average price is $6.65.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.08. The business had revenue of $20.41 million for the quarter, compared to analyst estimates of $16.29 million. Inovio Pharmaceuticals had a negative return on equity of 63.67% and a negative net margin of 153.46%. The firm’s revenue was up 229.2% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.26) EPS. On average, equities research analysts forecast that Inovio Pharmaceuticals will post ($0.92) EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Inovio Pharmaceuticals, Inc. (INO) Earns Outperform Rating from Analysts at Royal Bank Of Canada” was posted by Watch List News and is the property of of Watch List News. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://www.watchlistnews.com/inovio-pharmaceuticals-inc-ino-earns-outperform-rating-from-analysts-at-royal-bank-of-canada/1638342.html.

Hedge funds and other institutional investors have recently modified their holdings of the business. Wasatch Advisors Inc. grew its holdings in Inovio Pharmaceuticals by 43.6% in the 2nd quarter. Wasatch Advisors Inc. now owns 2,610,818 shares of the biopharmaceutical company’s stock valued at $20,469,000 after buying an additional 793,306 shares in the last quarter. Wells Fargo & Company MN grew its holdings in Inovio Pharmaceuticals by 28.9% in the 1st quarter. Wells Fargo & Company MN now owns 124,565 shares of the biopharmaceutical company’s stock valued at $825,000 after buying an additional 27,898 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in Inovio Pharmaceuticals by 3.6% in the 1st quarter. Bank of New York Mellon Corp now owns 342,348 shares of the biopharmaceutical company’s stock valued at $2,266,000 after buying an additional 11,765 shares in the last quarter. ARK Investment Management LLC grew its holdings in Inovio Pharmaceuticals by 79.2% in the 2nd quarter. ARK Investment Management LLC now owns 65,901 shares of the biopharmaceutical company’s stock valued at $517,000 after buying an additional 29,128 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in Inovio Pharmaceuticals by 7.9% in the 1st quarter. Vanguard Group Inc. now owns 3,098,055 shares of the biopharmaceutical company’s stock valued at $20,510,000 after buying an additional 226,861 shares in the last quarter. 24.83% of the stock is currently owned by hedge funds and other institutional investors.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Analyst Recommendations for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.